Liver Protein Fetuin-A Drives Glucagon Release, New Study Finds

A glycoprotein manufactured by the liver, long implicated in insulin resistance and chronic inflammation, may also be pulling the strings of the pancreas’ least understood hormone cell. In a study published in the Journal of Translational Medicine, researchers at the University Magna Graecia of Catanzaro report that alpha 2-HS glycoprotein, better known as Fetuin-A or Fet-A, stimulates both the synthesis and the secretion of glucagon, the hormone that raises blood sugar when glucose runs low. The team traced the effect through cell culture experiments, animal studies, and a human cohort, building a three-tier case that Fetuin-A is not merely a bystander in metabolic disease but an active modulator of pancreatic alpha cell behavior. The findings, led by first authors Elettra Mancuso and Carolina Averta under the direction of corresponding author Gaia Chiara Mannino and senior investigator Francesco Andreozzi, open a fresh line of inquiry into how the liver and the endocrine pancreas communicate in health and disease.

Glucagon is the hormonal mirror image of insulin. While insulin ushers glucose out of the bloodstream and into tissues, glucagon does the opposite, instructing the liver to release stored glucose when fasting or hypoglycemia threatens the brain’s energy supply. It is produced by alpha cells, a small but critical population within the pancreatic islets that has historically received far less attention than the insulin-secreting beta cells. In type 2 diabetes, the glucagon axis is often deranged: alpha cells fail to suppress glucagon after meals, contributing to the hyperglycemia that defines the disease, while paradoxically overreacting during hypoglycemic episodes. Understanding what drives alpha cell dysfunction has therefore become a pressing question, and the new study suggests that a circulating liver-derived protein may be part of the answer.

Fetuin-A, encoded in humans by the AHSG gene, is produced almost exclusively by hepatocytes and circulates at high concentrations in the blood. Previous research had established associations between elevated Fetuin-A levels, insulin resistance, fatty liver disease, and low-grade inflammation, but its influence on alpha cell function had never been systematically explored. To probe that gap, the investigators turned to Alpha TC1 clone 6 cells, a mouse pancreatic alpha cell line widely used to study glucagon biology. They exposed the cells to high concentrations of Fet-A under hyperglycemic conditions and then switched them to low glucose to trigger glucagon synthesis, a protocol designed to mimic the metabolic swings that alpha cells experience in vivo.

The results were striking. Fetuin-A treatment increased the expression of preproglucagon mRNA, the genetic template from which glucagon is made, indicating that the protein acts at the level of gene transcription rather than merely prompting the release of preformed hormone. Mechanistically, the team found that Fet-A activated inflammatory signaling through Toll-like receptor 4, or TLR4, the same innate immune receptor that recognizes bacterial lipopolysaccharide. When the researchers silenced the TLR4 gene using small interfering RNA, the stimulatory effect of Fetuin-A on glucagon synthesis vanished, demonstrating that the receptor is a necessary intermediary. Pharmacological inhibitors corroborated the finding, and Western blotting confirmed that the alpha cells express TLR4 basally, giving the pathway a plausible structural foothold.

But the study did not stop at inflammation. A second, and arguably more novel, mechanism emerged from the interaction between Fetuin-A and insulin-like growth factor 1, or IGF-1. Under normal circumstances, IGF-1 suppresses glucagon synthesis during hypoglycemia through the PI3K/Akt/FoxO1 signaling cascade, a well-characterized intracellular pathway that transmits growth factor signals from the cell surface to the nucleus. The researchers found that Fetuin-A disrupted this braking mechanism, impairing IGF-1’s ability to dampen glucagon production precisely when suppression matters most. In other words, when blood sugar drops and the body needs to restrain glucagon’s counter-regulatory surge, elevated Fetuin-A appears to loosen the leash.

To understand how a circulating glycoprotein could interfere with a receptor-driven pathway, the team turned to cell-surface confocal microscopy and molecular docking. The imaging experiments revealed a dose-dependent co-localization of Fetuin-A with the IGF-1 receptor on the alpha cell membrane, suggesting that the two molecules physically occupy overlapping territory. Docking analysis predicted potential structural overlap within the receptor’s extracellular domain, and sequence alignment studies showed that the relevant beta-subunit domain is spatially conserved across human and mouse insulin and IGF-1 receptors. Taken together, the data support a model of steric interference: Fetuin-A binds at or near the receptor’s ligand-binding region, physically obstructing IGF-1 from engaging its target and thereby blunting the downstream signal that normally curtails glucagon synthesis.

The cell culture findings were then tested in living organisms. The researchers administered Fetuin-A to CD-1 mice for three consecutive days, with a saline-treated control group for comparison. The treated animals showed increased circulating glucagon concentrations, along with elevated levels of inflammatory cytokines, mirroring the dual inflammatory and hormonal signature observed in the cell experiments. All animal protocols were approved by the local Animal Care Committee and conducted in accordance with European directive 2010/63/EU, the ARRIVE guidelines, and the 3R principle, lending regulatory rigor to the in vivo component of the work.

The final and most clinically consequential piece of evidence came from humans. The team analyzed data from 93 non-diabetic adults enrolled in the CATAMERI study, the CAtanzaro MEtabolic RIsk cohort, a long-running observational project examining cardiometabolic risk factors. Fasting plasma Fetuin-A concentrations were positively associated with fasting glucagon levels, and the association held up after statistical adjustment for age, sex, body mass index, insulin, and IGF-1. That independence matters: it argues that the relationship is not simply a byproduct of obesity, insulin status, or growth factor levels, but reflects a direct physiological link between the liver-derived protein and alpha cell output. Glucagon was measured using a chemiluminescence immunoassay, a sensitive and standardized method that strengthens confidence in the clinical measurement.

What emerges from the combined evidence is a coherent mechanistic story with potential implications for metabolic disease. If Fetuin-A, elevated in obesity and fatty liver, both inflames alpha cells through TLR4 and disables the IGF-1-mediated brake on glucagon synthesis, then the protein could help explain why hyperglucagonemia persists in insulin-resistant states even when glucose is abundant. The liver, in this framing, is not just a victim of hormonal miscommunication but an active participant, secreting a signal that reshapes the behavior of the very cells responsible for glucose counter-regulation. The authors also verified that Fet-A was not cytotoxic to the alpha cells across the concentration range tested, using MTT viability assays over 48 hours, which rules out the trivial explanation that the hormone changes simply reflect cell damage or death.

Cautions remain, as they always do in translational research. The cell line is murine, the mouse experiments involved exogenous protein administration rather than chronic endogenous elevation, and the human data are cross-sectional, showing association rather than causation. Whether lowering Fetuin-A would normalize glucagon levels in people with diabetes is a question for future interventional studies. Still, the convergence of evidence across three biological levels, from transcriptional regulation in cultured cells to hormone measurements in mice and statistical associations in a well-characterized human cohort, gives the hypothesis unusual solidity. The work was supported by Italian national research funding programs, including PNRR and PRIN grants, and the authors report no competing interests. As the field increasingly recognizes alpha cells as active drivers of dysglycemia rather than passive bystanders, Fetuin-A now sits squarely on the list of molecular suspects worth pursuing, and therapies aimed at interrupting its interaction with TLR4 or the IGF-1 receptor may one day earn a place in the metabolic medicine arsenal.

Subject of Research: The role of the liver-derived glycoprotein Fetuin-A in regulating pancreatic alpha cell glucagon synthesis and secretion

Article Title: Alpha 2-HS glycoprotein increases glucagon synthesis and secretion in cells, mice, and humans

Article References: Mancuso, E., Averta, C., Rubino, M., Citraro, R., Palummo, A., Servello, A., Belviso, S., Massimino, M., Mannino, G. C., De Sarro, G., Sesti, G., & Andreozzi, F. (2026). Alpha 2-HS glycoprotein increases glucagon synthesis and secretion in cells, mice, and humans. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08965-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08965-7

Keywords: Fetuin-A, glucagon, pancreatic alpha cells, TLR4, IGF-1 receptor, inflammation, insulin resistance, type 2 diabetes, liver, metabolic disease, PI3K/Akt/FoxO1, CATAMERI study